In particular, alongside the traditional concept of targeting DDR enzymes such as PARP1, WEE1, and ATR, harnessing the epigenomic changes in cancer cells represents another exciting direction as DNA damage repair largely depends on chromatin configuration [3]. The gene discussed is PARP1; the disease is cancer.